tetano
Editor, Senior Moderator
Hematol Transfus Cell Ther
. 2023 Feb 9.
doi: 10.1016/j.htct.2023.01.004. Online ahead of print.
Effects of therapeutic plasma exchange on a cohort of patients with severe coronavirus infection: real world evidence from Brazil
Paula Menezes Schiefferdecker[SUP] 1 [/SUP], Iara Buselato Chen[SUP] 2 [/SUP], Fernanda Bronzel Bher[SUP] 1 [/SUP], Leonardo Klettenberg Aciolli[SUP] 1 [/SUP], Geovana Bodanese[SUP] 1 [/SUP], Lucas Miyake Okumura[SUP] 3 [/SUP], Paulo Tadeu Rodrigues de Almeida[SUP] 1 4 [/SUP]
Affiliations
Abstract
Introduction: The therapeutic plasma exchange (TPE) controls the systemic cytokine level and might improve the immune response in patients with severe Coronavirus (COVID-19) infection. To date, in developing countries, no study has explored the effectiveness and risk factors in a population with severe COVID-19 exposed to the TPE.
Method: We described the risk factors associated with survival rates higher than 28 days and length of stay (LOS) in the intensive care unit (ICU) shorter than 15 days. Severe COVID-19 cases treated with TPE were included, from August 2020 to June 2021. Survival analysis with Kaplan-Meier curves, log-rank tests and multivariate logistic regressions were conducted to assess patient-related factors that could predict a higher survival rate and the ICU LOS.
Results: A total of 99 patients with severe COVID-19 who had received TPE were followed during their hospital stay and for 28 days after discharge. The sample was composed of men (63%) aged 56 ± 16 years. The overall survival rate at 28 days was 80%. The ICU LOS (p = 0.0165) and mechanical ventilation (MV) (p = 0.00008) were considered factors that could increase the risk of death. Patient-related factors that influenced the 28-day mortality were the smoking status (OR = 5.8; 95%CI 1.5, 22) and history of oncologic or non-malignant hematologic diseases (OR = 5.9; 95%CI 1.2, 29).
Conclusion: Patients with severe COVID-19 exposed to the TPE were associated with a 20% risk of death in a 28-day observation window, appearing to be lower than previous treatments. Active smoking, cancer and immunosuppressive conditions should be considered as relevant variables to be controlled in future trials on the TPE and COVID-19.
Keywords: Coronavirus; Mortality; Plasma; Sars-cov-2; Therapeutic plasma exchange.
. 2023 Feb 9.
doi: 10.1016/j.htct.2023.01.004. Online ahead of print.
Effects of therapeutic plasma exchange on a cohort of patients with severe coronavirus infection: real world evidence from Brazil
Paula Menezes Schiefferdecker[SUP] 1 [/SUP], Iara Buselato Chen[SUP] 2 [/SUP], Fernanda Bronzel Bher[SUP] 1 [/SUP], Leonardo Klettenberg Aciolli[SUP] 1 [/SUP], Geovana Bodanese[SUP] 1 [/SUP], Lucas Miyake Okumura[SUP] 3 [/SUP], Paulo Tadeu Rodrigues de Almeida[SUP] 1 4 [/SUP]
Affiliations
- PMID: 36785754
- PMCID: PMC9910014
- DOI: 10.1016/j.htct.2023.01.004
Abstract
Introduction: The therapeutic plasma exchange (TPE) controls the systemic cytokine level and might improve the immune response in patients with severe Coronavirus (COVID-19) infection. To date, in developing countries, no study has explored the effectiveness and risk factors in a population with severe COVID-19 exposed to the TPE.
Method: We described the risk factors associated with survival rates higher than 28 days and length of stay (LOS) in the intensive care unit (ICU) shorter than 15 days. Severe COVID-19 cases treated with TPE were included, from August 2020 to June 2021. Survival analysis with Kaplan-Meier curves, log-rank tests and multivariate logistic regressions were conducted to assess patient-related factors that could predict a higher survival rate and the ICU LOS.
Results: A total of 99 patients with severe COVID-19 who had received TPE were followed during their hospital stay and for 28 days after discharge. The sample was composed of men (63%) aged 56 ± 16 years. The overall survival rate at 28 days was 80%. The ICU LOS (p = 0.0165) and mechanical ventilation (MV) (p = 0.00008) were considered factors that could increase the risk of death. Patient-related factors that influenced the 28-day mortality were the smoking status (OR = 5.8; 95%CI 1.5, 22) and history of oncologic or non-malignant hematologic diseases (OR = 5.9; 95%CI 1.2, 29).
Conclusion: Patients with severe COVID-19 exposed to the TPE were associated with a 20% risk of death in a 28-day observation window, appearing to be lower than previous treatments. Active smoking, cancer and immunosuppressive conditions should be considered as relevant variables to be controlled in future trials on the TPE and COVID-19.
Keywords: Coronavirus; Mortality; Plasma; Sars-cov-2; Therapeutic plasma exchange.